Over a 10-year period, a prospective study followed Swedish patients without arthritis who tested positive for ACPA and had musculoskeletal pain, with the aim of finding out more about the disease course and prognostic factors [1]. Patients enrolled between 2010 and 2013 were followed for the development of clinical arthritis in ≥1 joint as the primary outcome, over a median period of 128 months. Additional outcomes included fulfilling ACR/EULAR classification criteria for RA.
The study cohort consisted of 82 patients with a mean age of 52 at baseline. Furthermore, 81% were women, 29% were rheumatoid factor (RF) positive, and the ACPA levels were categorised as high in 61% and low in 39% of cases.
Over the follow-up period, 63% progressed to clinical arthritis. “The median time to develop arthritis was 16 months,” Dr Simon Ahammar (Linköping University, Sweden) stated. At the 10-year clinical assessment, 40 out of the 66 (60%) patients who completed the study had developed arthritis. While all of them fulfilled the ACR/EULAR criteria for RA, 28% of them were not diagnosed with clinical RA. The diagnoses of these patients were transient arthritis without the need for a DMARD treatment (13%), osteoarthritis (8%), and psoriatic arthritis (7%).
A multivariate model identified 3 significant predictors of long-term progression to arthritis: ACPA levels (P<0.001), RF levels (P=0.020), and high RF levels (P=0.018), the latter detected after dichotomisation into high and low categories.
“Other factors, such as shared epitope or symptom duration, tender joint counts, or C-reactive protein levels, were not predictive of arthritis development,” Dr Ahammar informed. He concluded by noting that a future analysis of this cohort will include radiographic findings.
- Ahammar S, et al. Results of a 10-year prospective follow-up of patients with musculoskeletal pain and anti-citrullinated protein antibodies -not every arthritis is rheumatoid arthritis, despite criteria fulfilment. OP0110, EULAR 2025, 11–14 June, Barcelona, Spain.
Posted on
Previous Article
« T2T strategy in gout lowers cardiovascular risk Next Article
Earlier add-on treatment in myasthenia gravis improves outcomes »
« T2T strategy in gout lowers cardiovascular risk Next Article
Earlier add-on treatment in myasthenia gravis improves outcomes »
Table of Contents: EULAR 2025
Featured articles
Gout: novel compound as a future option for refractory patients?
Online First
ACPA positivity plus musculoskeletal pain does not equal clinical arthritis over time for all
T2T strategy in gout lowers cardiovascular risk
Obinutuzumab shows robust efficacy across different renal endpoints in lupus nephritis
SSc-ILD: Combination of rituximab and mycophenolate mofetil not superior to treatment with either agent alone
FcRn blockade: a promising targeted treatment option for inflammatory idiopathic myopathy
Fine particulate matter air pollution linked to increased ANA positivity
Gout: novel compound as a future option for refractory patients?
Inhibition of TLR7 and 8: A new way to treat lupus?
TYK2-inhibition in PsA: zasocitinib shows benefits in minimal disease activity and PASI
Rapid radiographic improvement with IL-23 blockade in biologic-naïve PsA patients
Use of Axia significantly improves axSpA outcomes
Beneficial treatment with leflunomide and hydroxychloroquine combination in Sjögren’s Disease
A sequential romosozumab-denosumab combination may improve lumbar BMD in glucocorticoid-induced osteoporosis
First-in-class oral TYK2 inhibitor shows rapid efficacy in PsA
Related Articles

July 21, 2022
How to treat enthesitis in 2022
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com